Our team

About us

We founded Cedilla at a time of fundamental and rapidly growing insight into the mechanisms underlying protein stability. Small molecules that degrade or stablize target proteins are precedented, but have been discovered serendipitously. Cedilla is taking an integrated approach to discover new drugs with this mode of action. Our present focus is to develop novel medicines in oncology, but this approach will also be applicable to other fields, including central nervous system disorders and genetic diseases. Cedilla launched with $56.2 million in Series A funding from Third Rock Ventures.


Scientific founders

Board of directors


Third Rock Ventures is a leading health care venture firm focused on investing in, launching and building companies that make a difference in people’s lives. Third Rock collaborates closely with its strategic partners and entrepreneurs and has an extensive track record of managing value creation to deliver exceptional performance.